Merck KGaA (MKKGY)
| Market Cap | 66.45B +18.0% |
| Revenue (ttm) | 24.16B -1.7% |
| Net Income | 2.92B -10.2% |
| EPS | 6.72 -10.0% |
| Shares Out | n/a |
| PE Ratio | 22.76 |
| Forward PE | 16.09 |
| Dividend | 0.35 (1.17%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 69,825 |
| Open | 30.41 |
| Previous Close | 30.38 |
| Day's Range | 30.32 - 30.91 |
| 52-Week Range | 23.73 - 31.00 |
| Beta | 0.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial numbers in EUR Financial StatementsNews
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
Merck KGaA Q1 Earnings Call Highlights
Merck KGaA ETR: MRK reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its...
Merck KGaA Earnings Call Transcript: Q1 2026
Solid organic growth in Life Science and Electronics offset Healthcare declines, with upgraded 2026 guidance reflecting strong Process Solutions and robust cash flow. One-off gains and disciplined cost management supported margins despite FX headwinds.
Merck KGaA Quarterly report: Q1 2026
Merck KGaA has published its Q1 2026 quarterly earnings report on May 13, 2026.
Merck KGaA Slides: Q1 2026
Merck KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Merck KGaA Earnings release: Q1 2026
Merck KGaA released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Merck KGaA Earnings release: Q1 2026
Merck KGaA released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q1 2026
Merck KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Merck KGaA Slides: Investor presentation
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Germany's Merck KGaA Raises Guidance
The outlook lift comes on expectations of stronger momentum in the group's life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.
Merck KGaA lifts earnings outlook on stronger Life Science momentum
Germany's Merck KGaA on Wednesday raised its 2026 adjusted operating profit guidance range, citing stronger momentum at its Life Science division and delayed competition for its Mavenclad multipl...
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0...
Merck KGaA Transcript: AGM 2026
AGM 2026 highlighted strong financial growth, strategic investments in bioprocessing, rare diseases, and AI, and a leadership transition from Garijo to Beckmann. A stable EUR 2.2 dividend per share was proposed, with continued focus on resilience and innovation.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Merck KGaA Earnings Call Transcript: Q4 2025
Solid organic growth in Life Science and Healthcare offset macro and FX headwinds, with Electronics rebounding on AI-driven demand. 2026 guidance anticipates stable margins, mid-single-digit Life Science growth, and continued strength in Semiconductor Materials.
Merck KGaA Annual report: Q4 2025
Merck KGaA has published its Q4 2025 annual report on March 5, 2026.
Merck KGaA Earnings release: Q4 2025
Merck KGaA released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Merck KGaA Quarterly report: Q4 2025
Merck KGaA has published its Q4 2025 quarterly earnings report on March 5, 2026.
Merck KGaA Slides: Q4 2025
Merck KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Merck KGaA Earnings Call Transcript: Q4 2025
2025 results met guidance despite FX and geopolitical headwinds, with stable sales and EBITDA growth. Life Science and Healthcare showed organic growth, while Electronics benefited from AI-driven demand. 2026 guidance reflects ongoing FX risks and MAVENCLAD U.S. exclusivity loss.
Merck KGaA Earnings release: Q4 2025
Merck KGaA released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q4 2025
Merck KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
Merck KGaA sees earnings decline of up to 4%
Germany's Merck KGaA said on Thursday it expects 2026 adjusted operating profit to slip by up to 4%, excluding currency effects.
Merck KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Positioned for growth in innovation-driven markets, the group focuses on Process Solutions, rare diseases, and Semiconductor Solutions, supported by disciplined M&A and a customer-centric reorganization. Midterm guidance targets mid-single digit organic growth, with margin expansion and robust pipeline development, especially in rare diseases.